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Abstract
Long non-coding RNAs (lncRNAs) are comprised of RNA transcripts exceeding 200 nucleotides 
in length but lacking identifiable open reading frames (with rare exceptions). Herein, we highlight 
emerging evidence demonstrating that lncRNAs are critical regulators of liver metabolic function 
and diseases. We summarize current knowledges about dysregulated lncRNAs and outline the 
underlying molecular mechanisms by which lncRNAs control hepatic lipid ad glucose 
metabolism, as well as cholestatic liver disease. lncLSTR, Lnc18q22.2, SRA, HULC, MALAT1, 
lncLGR, MEG3, and H19, lncHR1, lnc-HC, APOA1-AS, DYNLRB2-2, and LeXis are included in 
the discussion.
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1. Introduction
With the development of high-throughput RNA sequencing technology in transcriptome 
analysis and bioinformatics prediction, RNA transcripts, that do not code proteins but that 
may have biological functions, have provided a new perspective in major physiological and 
pathological processes. It is estimated that more than 80% of the human genome is 
pervasively transcribed; however, protein-coding genes account for less than 2% of the 
human genome.1 This leaves the balance of the human genome to be transcribed into 
thousands of non-coding RNAs (ncRNAs). According to size, the ncRNA transcripts are 
arbitrarily categorized into two main subgroups: short ncRNA (<200bp) and long ncRNAs 
(lncRNAs) (>200bp). Short ncRNAs include highly abundant and functionally important 
RNAs such as transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), as well as small 
regulatory RNAs such as microRNAs, siRNAs, wipi-interacting RNA (piRNA).2 While 
lncRNAs are commonly defined as transcripts of more than 200 nucleotides in length that 
are not capable of being translated into proteins.3 Extensive studies have been conducted on 
miRNAs, however the functions of lncRNAs remain poorly understood.4,5 Recent studies 
have revealed that lncRNAs significantly impact on various biological processes as X-
inactivation, genomic imprinting, chromatin modification, cell fate specification, cell 
apoptosis, nuclear trafficking, and genome rearrangement.6
Herein, we focus on the role of lncRNAs in liver metabolic functions and associated liver 
diseases. This new emerging research field is expected to significantly increase our 
understanding the fundamental mechanisms contributing to various liver diseases with the 
goal of developing new diagnosis, prognosis and treatment strategies.
2. Characteristics of lncRNA
The majority of lncRNA are transcribed from RNA polymerase II and are often capped, 
spliced and poly-adenylated.7 Unlike mRNAs, lncRNAs are poorly conserved between 
humans and rodents. lncRNAs are expressed in a species- and tissue-specific, and 
developmentally regulated manner which may contribute to their unique function.8 Based on 
relationship to their location relative to that of nearby protein-coding genes, lncRNA are 
currently classed into five categories, namely i) sense; ii) antisense; iii) bidirectional; iv) 
intronic; and v) intergenic.9 As gene expression regulators, lncRNAs are involved in 
chromatin remodeling, epigenetic regulation, transcriptional and post-transcriptional 
regulation, processing of small RNAs, protein function, and other regulatory processes.10 
Mechanistically, molecular functions of lncRNAs are described as signals, decoys, guides, 
and scaffolds.11 The specific expression in specific cell types and stages of development as 
well as the response to environmental stimuli make lncRNAs as effective signals. As decoys, 
lncRNAs bind and promote protein degradation. LncRNAs can also bind and recruit 
regulatory molecules such as chromatin remodelers and transcription factors to specific gene 
targets to control gene expression. By binding different molecules with different domains, 
lncRNAs can also act as scaffolds, assembling a functional complex.12
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3. LncRNAs in hepatic lipid and glucose metabolism
As the major site for synthesis, metabolism, storage, and redistribution of carbohydrates, 
proteins, and lipids, liver plays a central role in metabolic homeostasis.13 Emerging studies 
have shown that many lncRNAs are key regulators of lipid and glucose metabolism. Lipid 
accumulation in liver is determined by the balance between lipogenesis and catabolic 
processes such as lipolysis, fatty acid b-oxidation and thermogenesis.14 The maintenance of 
glucose homeostasis results from the balance of glucose production and/or storage in the 
liver and glucose uptake in the peripheral tissues.15 Dysregulation of these processes leads to 
adiposity, dyslipidemia, and metabolic perturbations.16
3.1 lncLSTR
Analysis of metabolic organ-enriched lncRNA identified that lncLSTR exhibits liver-specific 
expression and its expression fluctuates in response to changes in energy levels and 
metabolic state.17 LncLSTR is an intergenic lncRNA and liver-specific knockdown of 
lncLSTR significantly reduced plasma triglyceride (TG) via enhancing tissue TG clearance. 
This reduced circulating level of TG in lncLSTR knockdown mice resulted from increased 
apoC2 expression and LPL activities through a FXR-mediated pathway. Mechanistically, 
lncLSTR has been shown to directly bind to TDP43, further relieve the transcriptional 
suppression of Cyp8b1 and lead to substantial change in bile acid composition. The altered 
bile composition activate FXR and apoC2 expression, resulting in enhanced TG clearance in 
mice.
3.2 Lnc18q22.2
Lnc18q22.2, a liver-specific lncRNA (RP11-484N16.1) on chromosome 18, has been shown 
to be markedly induced in the liver tissue of NASH patients, correlating with NASH grade, 
lobular inflammation and NAS score.18 Interesting, lnc18q22.2 is significantly associated 
with liver steatosis and steatohepatitis, but not with hepatocellular carcinoma in 44 
independent liver biopsies. Knockdown of lnc18q22.2 in hepatocyte cell lines reduced cell 
viability and promoted necrosis.
3.3 SRA
A steroid receptor coactivator, SRA, was reported existing in an SRC-1 complex and 
functioned as an RNA coactivator for non-steroid nuclear receptors.19 A recently study 
showed that the expression of liver adipose triglyceride lipase (ATGL) is induced in SRA 
knockout mice.20 SRA suppresses ATGL via inhibiting transcriptional activity of FOXO1 in 
an insulin-independent pathway, thus reducing FFA β-oxidation and promoting hepatic 
steatosis. SRA is also the first lncRNA reported to play a potential role in adipogenesis 
through regulation of PPARγ and P38/JNK phosphorylation.21
3.4 HULC
Highly upregulated in liver cancer (HULC), the first identified lncRNA specifically 
overexpressed in hepatocellular carcinoma (HCC), has been shown as an effective 
prognostic biomarker in many human cancers.22,23 HULC can be posttranscriptional 
destabilized by IGF2BP1 via recruiting the CCR4-NOT deadenylase complex, a major 
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component of the cytoplasmic RNA decay machinery.24 A recently study showed that 
HULC induced methylation of CpG islands in the miR-9 promoter through upregulation of 
DNMT1.25 The downregulation of miR-9 further enhanced lipogenesis and enriched 
intracellular triglycerides and cholesterol by activating PPARγ and ACSL1 in hepatoma 
cells.
3.5 MALAT1
Metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) is involved in the 
development of HCC and liver fibrosis.26,27 A recently study showed that MALAT1 
promoted hepatic steatosis and insulin resistance. MALAT1 induced hepatic lipid 
accumulation and insulin resistance by interacting with SREBP-1c and stabilizing its protein 
in hepatocytes.28 Knockdown of MALAT1 effectively reversed lipid aggregation and 
increased insulin sensitivity in ob/ob mice.
3.6 lncLGR
Glucose levels in mammals is tightly controlled through multiple mechanisms to meet 
systemic energy demands. As the major site of glucose regulation, the liver produces glucose 
through glycogenolysis and gluconeogenesis during fasting, while promoting glucose uptake 
and glycogen storage during feeding. Liver glucokinase repressor (lncLGR), a fasting-
induced lncRNA in the liver, has been shown to suppress glucokinase (GCK) transcription 
and glycogen storage in fasted mice.29 Mechanistically, lncLGR specifically binds to 
heterogenous nuclear ribonucleoprotein L (hnRNPL), an RNA-binding protein which is 
further confirmed to be recruited to the promoter of GCK and suppress its transcription.
3.7 MEG3
Maternally expressed gene 3 (MEG3) is upregulated in high-fat diet and ob/ob mice through 
histone acetylation.30 Knockdown of MEG3 remarkably abolishes hepatic TG accumulation, 
up- regulates glycogen content, and promotes glucose tolerance in high-fat diet mice and 
ob/ob mice. Another study showed that MEG3 was highly expressed in mouse islets and was 
down- regulated during the pathogenesis of diabetes.31 Moreover, the expression of MEG3 
was modulated by glucose both in vitro and in vivo. Knockdown of MEG3 reduced insulin 
synthesis, secretion, and increased beta cell apoptosis, leading to impaired glucose tolerance.
3.8 H19
H19 is one of the first discovered lncRNAs highly expressed in fetal mouse and human liver, 
but repressed in adult liver by zinc fingers and homeoboxes 2 (Zhx2).32 H19 is significantly 
up- regulated in mouse model of CCl4-induced tumors and in human fibrotic/cirrhotic liver.
33
 H19 plays a role in affecting transcription through chromatin remodeling. One study 
related H19 to steatosis by a lipid droplet protein PLIN2 which was significantly induced in 
fatty liver.22 H19 was up-regulated in the liver of high fat diet fed PLIN2 knockdown mice 
with decreased hepatic TG level.
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3.9 lncHR1
LncHR1 was recently identified as a novel human specific lncRNA, which was shown to 
reduce hepatic and plasma TG levels along with decreased expression of SREBP1c, FAS, 
and ACCα in high-fat diet model. In Huh7 cells, lncHR1 abolished oleic acid induced TG 
accumulation and cytosolic lipid droplets. Mechanistically, lncHR1 regulates hepatic lipid 
metabolism by suppressing SREBP1c promoter activity and negatively regulating SREBP1c 
and FAS expression.34
4. LncRNA in cholestatic liver disease
In hepatocytes, cholesterol homeostasis is maintained by a complex network involving 
cholesterol uptake, synthesis, intracellular transport, and excretion.35 As the end-products of 
cholesterol catabolism in the liver, bile acids (BAs) are secreted by the liver to aid in the 
digestion of fats and are reported as signaling molecules that regulate glucose, lipid, and 
energy metabolism.13,36 Cholestasis is a pathological condition that BAs are blocked to flow 
out of liver, resulting intrahepatic accumulation. High levels of toxic BAs cause bile duct 
epithelium damage, hepatocytes injury and inflammation.37 Chronic cholestasis then leads 
to liver fibrosis, cirrhosis, liver failure, hepatocellular arcinoma, and cholangiocarcinoma.
4.1 lnc-HC
A novel lncRNA named lnc-HC is up-regulated in HFD MetS rat liver to negatively regulate 
cholesterol metabolism by physically interacting with hnRNPA2B1 in hepatocytes.38 The 
lnc-HC- hnRNPA2B1 complex further binds to two target message RNAs Cyp7a1 or Abca1; 
both are critical for the conversion of cholesterol into BAs and for facilitating cholesterol 
efflux. Knockdown of lnc-HC significantly recovers glucose tolerance disorder, and 
improves total cholesterol, TG, and HDL-cholesterol in the HCD rat model.
4.2 APOA1-AS
Another potential group of lncRNAs that consist of 70% of total lncRNAs is natural 
antisense transcripts (NATs), which regulate sense gene expression in a positive or negative 
manner. APOA1-AS is transcribed from the opposed DNA strand to APO gene cluster and 
negatively regulates APOA1 expression in vitro and in vivo. As the major protein 
component of high- density lipoprotein in plasma and cofactor for the lecithin cholesterol 
acyltransferase, APOA1 plays a significant role in reverse cholesterol transport, promoting 
cholesterol efflux from tissues.39 APOA1-AS epigenetically inhibits APOA1 expression and 
multiple neighboring genes, though LSD1 and SUZ12 recruitment.40
4.3 H19
We reported that hepatic H19 expression was strikingly induced in Bcl2-induced cholestatic 
liver injury, which was alleviated by knockdown of H19.41 Hepatic overexpression of 
H19RNA facilitated the development of obstructive cholestatic liver fibrosis.42 
Mechanistically, H19 downregulated hepatic zinc finger E-box-binding homeobox 1 
(ZEB1), and impeded its suppression of epithelial cell adhesion molecule (EpCAM), which 
in turn augmented bile duct ligation (BDL)-induced liver fibrosis. In addition, H19RNA is 
upregulated in both PBC and PSC patients. Another group reported a similar role of H19 in 
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cholestasis. H19 was shown to be representing a key factor that causes the gender disparity 
of cholestatic liver injury not only in Mdr2 KO mice, and probably in human PSC patients.4
4.4 MEG3
MEG3, which was shown to promote hepatic insulin resistance, was down-regulated in the 
liver of mice fed with DDC.30,43 Recently, MEG3 was identified as a guide RNA scaffold to 
recruit PTBP1 to destabilize nuclear receptor Shp mRNA in cholestatic liver injury.44 
Overexpression of MEG3 RNA induced a rapid Shp mRNA degradation and elevation of 
liver injury enzymes such as ALT and AST in mouse liver, and disrupted bile acids 
homeostasis. Moreover, the expression of MEG3 was also inhibited by SHP via a CREB-
dependent feedback regulation.
4.5 DYNLRB2-2
lincRNA-DYNLRB2-2 was reported to be significantly induced in THP-1 macrophage-
derived foam cells by Ox-LDL in a dose and time-dependent manner.45 Up-regulated 
lincRNA- DYNLRB2-2 promoted ABCA1 expression, which plays an essential role in 
cholesterol metabolism and inflammation, via inducing the expression of G protein-coupled 
receptor 119 (GPR119) and activating GLP-1R pathway.
4.6 LeXis
Liver-expressed LXR-induced sequence (LeXis), an lncRNA robustly induced in primary 
mouse hepatocytes treated with LXR agonist GW3965, decreased serum cholesterol, but not 
triglycerides in a mouse model.46 LeXis has been shown to inhibit cholesterol biosynthesis 
by associating with and affecting the DNA interaction of Raly which is required for the 
maximal expression of cholesterologenic genes in mouse liver.
5. Conclusions and future perspectives
LncRNAs control several important aspects of liver function involved in the 
pathophysiology of human liver injury and disease.5 The microRNAs (miRNAs) comprise a 
class of short single- stranded non-coding RNAs that regulate gene expression mainly 
through post-transcriptional regulation by binding to the 3′UTRs of target mRNAs. For 
example, a new study demonstrated that miR-127 modulates the pluripotency of liver tumor 
initiating cells by targeting HMGB2.47 Compared to miRNAs, lncRNAs can exert their 
diverse functions through interaction with proteins, miRNAs and mRNAs.48 Hepatocellular 
carcinoma (HCC) is one of the most common cancers in the world.49 Recent studies have 
also identified the critical roles of lncRNAs in the pathogenesis and metastasis of HCC 
through regulating tumor growth and proliferation, metastasis and invasion, and apoptosis.48 
Novel concepts related to lncRNAs and liver physiology have been successfully integrated 
into the drug development process to develop effective therapies. Continued efforts are still 
needed to expand the current knowledge in order to develop lncRNA-based therapeutics for 
the treatment of chronic liver diseases.
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Figure 1. 
Diagram depicting the regulatory role of lncRNAs in live metabolism and disease. LncRNAs 
(dark blue) are presented in three groups based on their function. Target genes are indicated 
on the right side of each lncRNAs (brown).
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Table 1
LncRNAs in Metabolic Liver Diseases
Metabolic liver diseases LncRNAs Reference
Hepatic lipid metabolism lncLSTR [17]
Lnc18q22.2 [18]
SRA [19],[20],[21]
HULC [24],[25]
MALAT1 [28]
LncHR1 [34]
Hepatic glucose metabolism MALAT1 [28]
lncLGR [29]
MEG3 [30],[31]
H19 [22],[32]
Cholestatic liver disease lnc-HC [38]
APOA1-AS [39],[40]
H19 [4],[41],[42]
MEG3 [30],[43],[44]
lincRNA-DYNLRB2-2 [45]
LeXis [46]
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